



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 49/00, C07H 21/04, C12N 5/06, 15/06, 15/07</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/27395</b> <b>(43) International Publication Date:</b> 12 September 1996 (12.09.96)
<b>(21) International Application Number:</b> PCT/US96/02751 <b>(22) International Filing Date:</b> 1 March 1996 (01.03.96) <b>(30) Priority Data:</b> 08/398,301                      3 March 1995 (03.03.95)                      US <b>(71) Applicant:</b> CEPHALON, INC. [US/US]; 145 Brandywine Parkway, West Chester, PA 19380 (US). <b>(72) Inventors:</b> SCOTT, Richard, W.; 5 Single Lane, Wallingford, PA 19086 (US). REAUME, Andrew, G.; 134 B. Hampton Court, West Chester, PA 19380 (US). HOFFMAN, Eric, K.; 329 B Baker Circle, West Chester, PA 19380 (US). <b>(74) Agents:</b> MILLER, Suzanne, E. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris, One Liberty Place - 46th floor, Philadelphia, PA 19103 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> GENE-TARGETED NON-HUMAN MAMMALS DEFICIENT IN THE SOD-1 GENE  <b>(57) Abstract</b>  Gene-targeted heterozygous and homozygous SOD-1 null non-human mammals, methods for producing them, and methods for use are described. Deletion vectors and gene-targeted cells are also described, as are methods for producing and using the same.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**GENE-TARGETED NON-HUMAN MAMMALS DEFICIENT IN THE SOD-1 GENE****Field of the Invention**

This invention generally concerns gene-targeted non-human mammals; particularly, gene-targeted mice  
5 deficient in the normal SOD-1 gene; and, more particularly, gene-targeted mice deficient in the normal SOD-1 gene incapable of expressing the Cu/Zn SOD protein.

**Background of the Invention**

The molecular reduction of oxygen to water during  
10 oxidative phosphorylation results inevitably in the production of superoxide radicals (" $O_2^{\cdot-}$ ") that are reactive oxygen species containing an unpaired electron orbital. Superoxides act as either reductants or oxidants and can form other reactive species including the hydroxyl radical  
15 (" $OH^{\cdot}$ ") through interaction with iron (Haber-Weiss reaction) and peroxynitrite by reaction with nitric oxide. Reactive oxygen species attack proteins, DNA, and membrane lipids, thereby disrupting cellular function and integrity.

The primary defenses against the superoxide  
20 radicals are the superoxide dismutase enzymes (SOD) that catalyze the dismutation of superoxide to hydrogen peroxide. Three forms of SOD are known to exist in mammals: cytoplasmic SOD (Cu/Zn SOD), mitochondrial SOD (Mn SOD), and extracellular Cu/Zn SOD (EC-SOD). In mammals, SOD-1 refers  
25 to the gene that encodes Cu/Zn SOD, SOD-2 refers to the gene that encodes Mn SOD, and SOD-3 refers to the gene that encodes EC-SOD.

Cu/Zn SOD is a homodimeric protein of 32 kD that is localized to the cytoplasm and, perhaps, peroxisomes. It is

- 2 -

produced constitutively in all cell types and is the most abundant SOD. High to moderate levels of Cu/Zn SOD are found in erythrocytes, the liver, skeletal muscle, and the brain. Mn SOD is a tetrameric protein localized to  
5 mitochondria and is found at approximately 5 to 10% of the levels of Cu/Zn SOD in cells. EC-SOD is a tetrameric protein evolutionarily related to Cu/Zn SOD that is found at low levels in plasma.

SOD-1 has been isolated and cloned from many  
10 different organisms. The complete amino acid sequences of Cu/Zn SOD from 11 different species have been compared. A high degree of homology is evident among those of vertebrate origin and the metal binding sites appear to be conserved in all the species. (Bannister et al., *CRC Critical Reviews in*  
15 *Biochemistry*, 22(2): 111-180, 1987, incorporated herein by reference.)

The human Cu/Zn SOD has 153 amino acids per monomeric subunit and is encoded by a single-copy gene on chromosome 21. (Tan et al., *J. Exp. Med.*, 137: 317-330,  
20 1973.) Human SOD-1 and cDNA have been cloned and sequenced. (U.S. Patent No. 5,196,335, issued to Yoram Groner on March 23, 1993; U.S. Patent No. 5,252,476, issued to Halliwell et al. on October 12, 1993, both incorporated herein by reference.) A full-length cDNA for murine Cu/Zn SOD has  
25 been isolated (Bewley, G. C., *Nucleic Acids Res.*, 16:2728, 1988, incorporated herein by reference) and the structure of the single-copy gene on chromosome 16 has been reported. (Benedetto et al., *Gene*, 99: 191-195, 1991.)

Oxidative stress has been implicated in normal  
30 aging and many human pathological conditions. (J.M.C. Gutteridge, *Free Rad. Res. Comms.*, 19: 141-158, 1993, incorporated herein by reference; Halliwell and Gutteridge, Methods in Enzymology, Vol. 186, pp. 1-75, 1990.) Some  
35 examples include stroke, head and spinal cord trauma, Alzheimer's disease, atherosclerosis, Parkinson's disease, and Huntington's disease. Major sources of free radical production, including ischemia/reperfusion, inflammation,

- 3 -

and mitochondrial injury, are common features of many of these conditions. Diseases in which reduced SOD activity may play a role include, for example, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Fanconi's anemia and  
5 aluminum toxicity.

A detrimental role for the superoxide radical in human disease is supported in animal models of disease processes using transgenic mice overexpressing Cu/Zn SOD. Chan et al., *Acta Neurochirurgica. Suppl.*, 51: 245-247,  
10 1990, reported that cortical neurons isolated from transgenic mice overexpressing Cu/Zn SOD two to threefold relative to normal Cu/Zn SOD levels are protected against glutamate neurotoxicity *in vitro*. Neuroprotection is also conferred in Cu/Zn SOD transgenic mice against focal  
15 cerebral ischemia (Kinouchi et al., *Proc. Natl. Acad. Sci. USA*, 88: 11158-11162, 1991) and N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced toxicity that causes damage similar to that observed in Parkinson's disease (Przedborski et al., *J. Neurosci.*, 12: 1658-1667, 1992).  
20 Evidence for a direct role of Cu/Zn SOD in human disease is exemplified by the disease ALS. ALS is a progressive paralytic disorder caused by the degeneration of large motor neurons of the brain and spinal cord and is usually fatal within five years of onset of symptoms.  
25 Approximately 90% of ALS is "sporadic", i.e., no familial history of the disease. Enhanced oxidative damage and stress in sporadic ALS patients, as evidenced by increases in protein carbonyl content and complex I electron transport activity, was reported by Bowling et al., *J. Neurochem.*,  
30 61(6): 2322-2325, 1993. Approximately 10 % of ALS is inherited as an autosomal dominant trait and is termed familial ALS (FALS). Recently, in a subset of FALS cases, 16 different missense mutations were identified within SOD-1 that resulted in a 40 to 50% reduction in the Cu/Zn SOD  
35 activity measured in red blood cell lysates. (Rosen et al., *Nature*, 362: 59-62, 1993; Deng, H.X. et al., *Science* 261: 1047-1051, 1993.)

- 4 -

The role of reduced Cu/Zn SOD activity in FALS is unclear, however, because transgenic mice overexpressing human Cu/Zn SOD bearing one of the FALS mutations develop progressive motor neuron loss similar to that observed in the human condition. (Gurney et al., *Science*, 264: 1772-1775, 1994). Ripps et al., *Proc. Natl. Acad. Sci. USA*, 92: 689-693, 1995, report that transgenic mice bearing a mutation in the mouse SOD-1 gene that corresponds to one of the changes in human FALS gene have high expression of the altered gene in the central nervous system which is associated with an age-related rapidly progressive decline of motor function accompanied by degenerative changes of motoneurons within the spinal cord, brain stem, and neocortex. The tissues of these transgenic mice had normal levels of total SOD activity. This suggests that the mutations confer a gain-of-function on the Cu/Zn SOD protein that contributes to disease onset. One possibility is that reduced Cu/Zn SOD activity measured in the FALS patients is a co-factor in the disease. (Gurney, *Science*, 266:1587, 1994.)

To determine whether decreased SOD activity could contribute to motor neuron loss, Cu/Zn SOD was inhibited chronically with antisense oligonucleotides or diethyldithiocarbamate in spinal cord organotypic cultures derived from rats. Chronic inhibition of Cu/Zn SOD resulted in the apoptotic degeneration of spinal neurons, including motor neurons. Motor neuron toxicity could be entirely prevented by the antioxidant N-acetylcysteine. (Rothstein et al., *Proc. Natl. Acad. Sci. USA*, 91: 4155-4159, 1994.) Similarly, Troy et al., *Proc. Natl. Acad. Sci. USA*, 91: 6384-6387, 1994, reported that inhibition of Cu/Zn SOD synthesis by antisense oligonucleotides in cultured PC12 cells (rat pheochromocytoma cells) results in apoptotic-like cell death in undifferentiated and nerve growth factor(NGF)-differentiated cultures. The authors suggest that free radical production caused by inhibition of Cu/Zn SOD is responsible for induction of the cell death pathway.

- 5 -

An animal model deficient in, or completely lacking, Cu/Zn SOD, would facilitate the elucidation of the role of Cu/Zn SOD and superoxide radicals in disease, and the testing of counteractive compounds. The development of an animal model affords both *in vivo* and *in vitro* testing opportunities as cultured cells from the SOD-1 deficient or lacking animals can be utilized for the *in vitro* testing. An animal model deficient in Cu/Zn SOD will permit one to determine whether there are compensatory responses of other anti-oxidant systems, including Mn SOD and EC-SOD.

It has been proposed that SOD is essential for normal aerobic life. (C. W. Olanow, *TINS*, 16: 439-444, 1993.) For example, non-mammalian SOD deficient organisms have been established which exhibit highly deleterious characteristics. *Escherichia coli* lacking SOD activity exhibit an oxygen-dependent auxotrophy for branched chain amino acids. These organisms are unable to grow aerobically on minimal media, and are highly sensitive to the free radical-producing agents paraquat and hydrogen peroxide. (Carlioz et al., *EMBO J.*, 5: 623-630, 1986.) Cu/Zn SOD deficient yeast (*Saccharomyces cerevisiae*) are intolerant to atmospheric levels of oxygen and are auxotrophic for lysine and methionine. (Chang et al., *JBC*, 266: 4417-4424, 1991.) Null mutations for Cu/Zn SOD in *Drosophila melanogaster* cause toxic hypersensitivities to oxidative stress conditions and a significant reduction in the adult lifespan. (Phillips et al., *Proc. Natl. Acad. Sci. USA*, 86: 2761-2765, 1989.)

### Summary of the Invention

In one aspect, the present invention relates to heterozygous SOD-1 null non-human mammals, preferably exemplified by a gene-targeted mouse lacking one normal copy (allele) of SOD-1, thereby producing a reduced amount of Cu/Zn SOD. In a preferred aspect, the invention relates to homozygous SOD-1 null non-human mammals exemplified by a gene-targeted mouse lacking both normal copies (alleles) of

- 6 -

SOD-1, thereby producing no measurable amount of Cu/Zn SOD protein.

In another aspect, the present invention relates to a recombinant DNA construct for effecting the gene targeting  
5 by means of homologous recombination.

In yet another aspect, the present invention relates to methods for testing the effectiveness of compounds in counteracting the effects of oxidative stress.

In a further aspect, the present invention relates  
10 to gene-targeted cells lacking at least one normal SOD-1 allele.

#### **Brief description of the drawings.**

Figure 1 depicts a prototype gene targeting strategy.

15 Figure 2 depicts mouse SOD-1 genomic clone maps (2a) and a composite determined therefrom (2b).

Figure 3 depicts restriction mapping with the FLASH® Nonradioactive Gene Mapping Kit. A typical restriction map for a genomic clone isolated from a Lambda  
20 DASH® II library is shown at the top of the figure.

Figure 4 depicts the SOD genomic map (4a) and targeting vector (4b).

Figure 5 depicts the construction of intermediate plasmid pPNTlox<sup>2</sup>.

25 Figure 6 depicts the construction of intermediate plasmid pSK18-9.

Figure 7 depicts the construction of intermediate plasmid pSOD3'homolTV.

Figure 8 depicts the construction of intermediate  
30 plasmid pSK EH69-2.

Figure 9 depicts the construction of deletion vector pSOD-TV.

Figure 10 depicts the strategy used to detect homologous recombination within mouse SOD-1.

35 Figure 11 depicts the measurement of Cu/Zn SOD concentration and activity levels in blood samples from



- 7 -

wild-type mice, and mice heterozygous and homozygous for the SOD-1 null allele.

#### Detailed Description

Because SOD is the initial defense against oxygen toxicity, and cytoplasmic Cu/Zn SOD represents a large fraction of SOD activity in mammals, it was not predictable whether mammals completely lacking Cu/Zn SOD, i.e., null for both alleles, could survive. With the advent of methods for introducing gene-targeted mutations in mammals currently exemplified in the art using mice, it was of interest to determine whether ablation or "knock-out" of the mouse normal SOD-1 gene could be accomplished resulting in gene-targeted, non-human mammals deficient in or lacking cytoplasmic Cu/Zn SOD activity, and whether mammals lacking Cu/Zn SOD activity would be able to survive. Such mutagenized mammals are useful for directly addressing the role of oxidative stress in any number of pathological conditions -- i.e., aging, radiation damage, immunological dysfunction, and neurological disorders -- in which free radical damage has been implicated.

As disclosed in more detail below, gene-targeted mammals according to the invention lacking one normal copy of SOD-1 (or SOD-1 allele) produce a reduced amount of Cu/Zn SOD. Such mammals are defined herein as "deficient" in SOD-1, and are termed "heterozygous SOD-1 null." Mammals according to the invention lacking both copies of normal SOD-1 produce substantially no, or no measurable amount, of Cu/Zn SOD. Such mammals are defined herein as "lacking" SOD-1, and are termed "homozygous SOD-1 null."

As used herein, the phrase "normal" or "normal copy" in reference to SOD-1 or SOD-1 allele means the gene encoding wild type amounts of enzymatically active Cu/Zn SOD protein in a wild type mammal whose genome includes such SOD-1. Thus, an animal lacking at least one normal copy of an allele, as defined herein, need not necessarily have that allele excised from the genome of that animal; rather, the

- 8 -

gene sequence can be sufficiently disrupted such that the expression of a protein encoded thereby is disrupted. Therefore, a mammal lacking at least one copy of a normal SOD-1 allele can, as defined herein, have a mutated SOD-1 allele that disrupts expression of the Cu/Zn SOD.

As used herein, the term "reduced amount" in reference to the amount of Cu/Zn SOD protein expressed in a gene-targeted mammal lacking one normal copy of SOD-1 gene means between about 25% and about 75% of wild-type Cu/Zn SOD protein typically expressed in a comparative mammal (e.g., a mouse in the case of the gene-targeted mouse).

As used herein, the term "no measurable amount" in reference to the amount of Cu/Zn SOD protein expressed in a gene-targeted mammal lacking both copies of normal SOD-1 means less than about 10% of wild-type Cu/Zn SOD protein normally expressed in a comparative mammal.

Methodologies for measurement of protein expressed by a gene are varied and well-known; analyses may be made, for example, using anti-Cu/Zn SOD protein antibody measurements of tissue samples such as exemplified in Example 5 below.

As used herein, the term "about" in reference to a numerical value means "+/- 10%" of the numerical value, e.g., "about 10%" means between 9% and 11%.

As used herein, the term "control" is given the definition ordinarily ascribed to the word in a scientific setting; thus, in situations where a putative therapeutic compound is provided to, e.g., a homozygous SOD-1 null mouse, to determine the effectiveness of the compound for counteracting the deleterious effects of oxidative stress, a "control" for such an analysis could be, e.g., a homozygous SOD-1 null mouse that is not provided with the compound; a SOD-1 null mammalian cell that is not provided with the compound, etc.

To implicate oxidative stress as an etiological factor in human neurological disease, deficits that develop

- 9 -

spontaneously in specific neuronal populations vulnerable to disease can be evaluated during normal aging. Examples of some deficits include the accumulation of oxidative damage on protein and enzymes (Reznick et al., Methods in Enzymology, Vol. 233, p. 363, 1994; Bowling et al., *supra*), DNA (Sanchez-Ramos et al., *Neurodegen.*, 3: 197-204, 1994) and membrane lipids (Dousset et al., Methods in Enzymology, Vol. 244, pp.459-469, 1994). Additional deficits include neuronal cell loss and behavioral abnormalities (Walsh and Cummins, *Physcol. Bull.*, 83: 482-504, 1976). More specifically, the influence of oxidative stress on apoptotic cell death *in vivo* can be examined in the SOD-1 deficient and SOD-1 lacking mammals during normal aging or after pharmacological lesions of particular neuronal populations. Apoptosis is established by measuring DNA cleavage, nuclear condensation, and cellular morphology (Rothstein et al., *Proc. Natl. Acad. Sci. USA*, 91: 4155-4159, 1994). Pharmacological lesions of interest include excitotoxicity (Miyamoto et al., *Exp. Neurol.*, 108: 38-45, 1990; Bazzett et al., *Exp. Neurol.* 120: 177-185, 1993), focal ischemia (Kinouchi et al., *Proc. Natl. Acad. Sci. USA*, 88: 11158-11162, 1991) and facial motor neuron axotomy (Yan et al., *J. Neurobiol.*, 24: 1555-1577, 1993).

Having established viable gene-targeted mammals which are both heterozygous SOD-1 null and homozygous SOD-1 null, analysis of the effects of having a reduced amount of Cu/Zn SOD protein, and no measurable amount of Cu/Zn SOD protein, respectively, on the development and behavior of such mammals can be determined. Oxidative stress can be potentiated by providing the heterozygotes and homozygotes a vitamin E/selenium deficient diet, exercise, and/or exposure to hyperbaric oxygen. Putative therapeutic agents for countering the effects of a Cu/Zn SOD deficiency can be analyzed and screened. Furthermore, the mammals can be used as a source of cells for culture for *in vitro* testing. Those skilled in the art will readily recognize the myriad of available choices for positive utilization of such

- 10 -

mammals.

Administration of the compound to be tested may be carried out by any appropriate means. In the case of the gene-targeted mammals, for example, administration may be

5 intracerebrally and/or intracerebroventricularly, and/or intravascularly, intralymphatically, parenterally, subcutaneously, intramuscularly, intraperitoneally, intrastitally, hyperbarically, and the like, using a variety of dosage forms and amounts, the particular route of

10 administration and the dosage form and amount being dependent on various factors such as the type of compound being tested, the age, weight, and type of mammal model etc. In the case of the gene-targeted cells, administration of the compound to be tested may be carried out, if desired, by

15 simply placing the compound in the cell culture medium. Generally, a lower dosage amount will be employed with the gene-targeted cells than with the gene-targeted mammals.

Deletion of the SOD-1 gene in a mouse genome is specifically disclosed below. Currently, gene-targeting

20 protocols utilized in the art are defined by the mouse; however, as the state of the gene-targeting art progresses to other mammals (i.e., rats, pigs, rabbits, non-human primates), the technique and methods disclosed below can rapidly be adapted thereto.

25 The deletion of SOD-1 was accomplished by first effecting the deletion of SOD-1 in embryonic stem (ES) cells using homologous recombination, resulting in mutagenized ES cells. The SOD-1 deletion was then incorporated into a mouse by introducing the mutagenized ES cells into a

30 developing mouse embryo. Breeding the resulting chimeric mice and their progeny produced some mice which were lacking one normal copy of SOD-1 (heterozygotes) and others which were lacking both normal copies (homozygotes).

Although we disclose herein our most preferred

35 strategy for the development of heterozygous SOD-1 null non-human mammals and homozygous SOD-1 null non-human mammals using a most preferred gene-targeting vector ("deletion

- 11 -

vector"), other strategies and targeting vectors will be readily apparent to those skilled in the art. Thus, the following disclosure is neither intended to be, nor to be construed as, a limitation on the disclosure or the claims to follow.

Figure 1 depicts a general paradigm for introducing deletions into a mammalian genome using homologous recombination, as has been reviewed by Capecchi, M. R., *Trends Genet.*, 5: 70-76, 1989 and Koller and Smithies, *Ann. Rev. Immunol.*, 10: 705-730, 1992, both incorporated herein by reference. However, other methods can be utilized for mutagenizing the mammalian genome. These include other methods of gene-targeting (for examples, see Capecchi, *supra*; Koeller and Smithies, *supra*) chemical mutagenesis (Rinchik, *Trends Genet.*, 7: 15-21, 1991) and insertional inactivation of genes by the random integration of vectors such as retroviruses (Robertson et al., *Ciba Found Symp.*, 165: 237-250, 1992).

A length of genomic DNA is first depicted by organizing it into regions (numbered 0 - 6 in Figure 1a). In Figure 1, region 3 is designated to be deleted. Homologous recombination using a gene-targeting vector is utilized. The type of gene-targeting vector used for the deletion of a gene is termed a replacement or deletion vector.

"Deletion vector" as used herein refers to a vector that includes one or more selectable marker sequences and two sequences of DNA homologous to the genomic DNA that flank the DNA gene sequence which is to be deleted. An "homologous sequence" as used herein is defined as a sequence at least about 90%, but preferably about 95%, identical to the corresponding target sequence. These flanking sequences are termed "arms of homology." In Figure 1b, the arms of homology are represented by regions 1-2 and 4-5. Preferably, these arms of homology are substantially isogenic for the corresponding flanking sequences in the cell being targeted or "target cell." A "substantially

- 12 -

isogenic" sequence is at least about 97-98% identical to the corresponding target sequence. The use of DNA isogenic to the target cells helps assure high efficiency of recombination with the target sequences. (teRiele et al.,  
5 *Proc. Natl. Acad. Sci. USA*, 89: 5128-5132, 1992.) The cumulative region of homology is longer than about 50 bp but is preferably about 2 kb or greater.

The deletion vector preferably includes at least a positive selection marker within the arms of homology to  
10 enable the scoring of recombination. Such positive selection markers can confer a phenotype not normally exhibited by wild-type mammals; for example, resistance to a substance normally toxic to the target cell. In this example, the positive selection marker can be flanked by  
15 loxP sites allowing for excision of the positive selection marker; see, for example, U.S. patent No. 4,959,317, issued to B. L. Sauer on September 29, 1990, incorporated herein by reference. In a further preferred embodiment, the deletion vector also includes one or more negative selection markers  
20 outside the arms of homology to facilitate identification of proper homologous recombinants. The negative selection markers can confer, for example, sensitivity to a substance not normally toxic to the target cell. The selection markers can be gene cassettes --ie., include both a promoter  
25 and an accompanying coding sequence. The result of homologous recombination of the gene-targeting vector with cellular DNA in the paradigm is shown in Figure 1c. As depicted therein, region 3 has been replaced by the positive selection marker.

30 In the specific deletion vector according to the present invention, the positive selection marker is neo<sup>r</sup>, a gene that encodes resistance to the neomycin analog G418, and the negative selection marker is the herpes simplex virus thymidine kinase gene (HSV-TK), a gene that encodes  
35 susceptibility to ganciclovir. Upon successful gene-targeting and homologous recombination, the positive selection marker is incorporated into the genome in place of

- 13 -

the gene to be deleted within the arms of homology, thereby making the gene-targeted cells resistant to G418, while the negative selection marker is excluded, thereby maintaining the cells' resistance to ganciclovir. Thus, to enrich for homologous recombinants, gene-targeted cells are grown in culture medium containing G418 to select for the presence of the neo<sup>r</sup> gene, and ganciclovir to select for the absence of the HSV-TK gene.

The "target cells" are those cells to be mutagenized. The target cells specifically disclosed herein are mouse embryonic stem cells. However, other cells can be utilized. The "gene-targeted cells" are those cells which are mutagenized. Gene-targeted cells lacking at least one normal copy of SOD-1 allele can be utilized in the generation of gene-targeted mice, for example. The gene-targeted cells which lack at least one normal SOD-1 allele can be utilized, for example, in high through-put screening of agents such as superoxide scavenging compounds. Such "screening cells" can be cryopreserved until utilized for such screening. See, for example, Oncea et al., *Int. Immunol.*, 6: 1161-1168, 1994 and Arbones et al., *Nat. Genet.*, 6: 90-97, 1994.

The specific procedure followed is detailed below. The following restriction enzymes, and their single letter codes, are referred to in the examples which follow: EcoRI (E), HindIII (H), KpnI (K), EcoRV (R), SalI (S) and NotI (N).

#### **Example 1**

##### **Cloning of Mouse SOD-1**

The mouse SOD-1 genomic DNA was cloned from a phage library created from 129/Sv mouse DNA partially digested with *Sau3A* and inserted into the *Bam*HI site of Lambda DASH<sup>II</sup> (Reaume et al., *Science*, in press, 1995). Using standard molecular biology techniques (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982) approximately  $1.2 \times 10^6$

- 14 -

recombinant bacteriophages were screened for the presence of SOD-1 sequences by hybridization with a 900 base pair (bp), radiolabelled SOD-1 intron-specific DNA probe. This 900 bp probe was generated by polymerase chain reaction (PCR) amplification (Mullis and Faloona, Methods in Enzymology, Vol. 155, pp. 335-350, 1987, incorporated herein by reference) of mouse genomic DNA using primers EH100 (ACC GGA ATT CCA TAT AAG GAT ATA TAC A; SEQ ID NO:1) and EH101 (TAG CGA ATT CAG GTT TGA ATG ATC AAG T; SEQ ID NO:2) which hybridize to each end of the SOD-1 intron 4 (Figure 2b). The approximate placement of the 5 SOD-1 exons is shown in Figure 2b as based on data from Bendetto et al., *Gene*, 99: 191-195, 1991, incorporated herein by reference, and marked above the map with bold numbers. The corresponding introns are numbered below the map in bold italics.

The amplified fragment was separated from the other components of the reaction by electrophoresis on a 1.0% agarose gel, and purified using GeneClean<sup>®</sup>II (Bio 101, Inc., La Jolla, CA). Purified probe DNA was radioactively labelled with <sup>32</sup>P-dCTP by the random primer method using materials and methods supplied by the kit manufacturer (Multiprime DNA Labeling System; Amersham Life Sciences, Arlington Heights, IL).

From this screen, 9 clones were identified which hybridized to the SOD-1 intron probe:  $\lambda$ SOD12,  $\lambda$ SOD72,  $\lambda$ SOD20I,  $\lambda$ SOD18,  $\lambda$ SOD69,  $\lambda$ SOD20G,  $\lambda$ SOD47,  $\lambda$ SOD67, and  $\lambda$ SOD65 (Figure 2a). These clones were purified by limiting dilution and plaque hybridization with the SOD-1 intron 4 probe (Maniatis et al., 1982, *supra*).

For each clone, DNA was prepared from bacteriophage particles first purified on a CsCl gradient (Maniatis et al., 1982, *supra*). Restriction maps were then generated for each of the cloned inserts using the FLASH<sup>®</sup> Nonradioactive Gene Mapping Kit (Stratagene<sup>®</sup> Inc., La Jolla, CA), as summarized in Figure 3. This method of restriction enzyme mapping involves first completely digesting 10  $\mu$ g of the phage DNA with the restriction enzyme NotI using standard



- 15 -

restriction enzyme digest conditions (Maniatis et al., 1982, *supra*). *NotI* cuts all clones in the vector DNA at either end of the cloned insert, leaving a T3 bacteriophage promoter attached to one end of the insert and a T7 bacteriophage promoter attached to the other end. The *NotI* digested DNA was then partially digested with the enzyme *EcoRI*, as an example, using limiting amounts of enzyme (0.2 units/ $\mu$ g DNA), in an 84  $\mu$ l reaction volume at 37°C. Aliquots (26  $\mu$ l) were removed after 3 minutes, 12 minutes, and 40 minutes and the digest reaction was stopped by the addition of 1  $\mu$ l of 0.5 M EDTA. DNA from all three time points was resolved on a 0.7% agarose gel, visualized by ethidium bromide staining, and then transferred to a GeneScreen Plus<sup>®</sup> membrane (NEN<sup>®</sup> Research Products, Boston, MA) by capillary transfer (Maniatis et al., 1982, *supra*). The membrane was hybridized with an alkaline phosphatase labelled oligonucleotide that was specific for the T3 promoter (supplied with the FLASH<sup>®</sup> kit) using reagents and methods supplied by the kit manufacturer. After hybridization, the membrane was washed and developed with a chemiluminescent-yielding substrate and then exposed to X-ray film in the dark for approximately 60 minutes.

The oligonucleotide probes effectively label one end of the insert. By determining the positions of the bands on the X-ray film and calculating the DNA size to which they correspond, it was possible to determine the position of the *EcoRI* sites relative to the T3 end of the insert. These results were then complemented by stripping the probe off of the membrane, and rehybridizing with a T7-specific oligonucleotide in order to determine the positions of the *EcoRI* sites relative to the T7 end of the insert. This process was repeated using the enzymes *HindIII* and *KpnI*.

The results of restriction mapping of the 9 different SOD genomic clones using the FLASH<sup>®</sup> Nonradioactive Gene Mapping Kit (Stratagene<sup>®</sup> Inc., La Jolla, CA) are depicted in Figure 2a. Some clones were isolated multiple

- 16 -

times and therefore have more than one name. By comparing the restriction enzyme maps of the different overlapping clones, a composite map was assembled (Figure 2b). Of the 9 original clones isolated, a total of six independent clones  
5 were identified.

## Example 2

### Construction of a Deletion Vector

Examination of the published report that describes the structure of the mouse SOD-1 gene (Bendetto, et al.,  
10 *supra*), revealed that the entire coding sequence of the mouse SOD-1 gene is within a 7.2 kb *EcoRI* fragment of DNA (Figure 2b). Based on available restriction site data and preferred sizes for arms of homology (Deng et al., *Mol. Cell. Biol.*, 12: 3365-3371, 1992; Zhang et al., *Mol. Cell.*  
15 *Biol.*, 14: 2402-2410, 1994), a 4.9 kb *HindIII-EcoRI* fragment was selected for the 5'-arm of homology and a 3.3 kb *KpnI-EcoRV* fragment was selected for the 3' arm (Figure 4a). A targeting vector was created by isolating these two fragments and placing them into a plasmid which contained a  
20 *neo<sup>r</sup>* cassette (a neomycin phosphotransferase gene linked to a phosphoglycerate kinase promoter) as a positive selection marker, a TK cassette (a Herpes simplex virus thymidine kinase gene linked to a phosphoglycerate kinase promoter) as a negative selection marker, and linker sequences, to  
25 produce the deletion vector pSOD-TV. The process is set forth in detail below.

Construction of the Intermediate Plasmid pPNTlox<sup>2</sup> pSOD-TV was created from a derivative of pPNT (Tybulewicz, et al., *Cell*, 65: 1153-1163, 1991, incorporated herein by reference;  
30 obtained from Dr. Richard Mulligan, MIT, Cambridge, MA) by first inserting two oligonucleotide linkers on each side of the *neo<sup>r</sup>* cassette creating the intermediate plasmid pPNTlox<sup>2</sup> (Figure 5). A double-stranded 79 base pair 5' linker having *Sall*, *HpaI*, and *NsiI* sites was created by annealing two  
35 single-stranded oligonucleotides that overlap at their 3' ends and then filling in the remaining single-stranded

- 17 -

regions with the Klenow fragment of DNA polymerase I. The oligonucleotides PNT Not (GGA AAG AAT GCG GCC GCT GTC GAC GTT AAC ATG CAT ATA ACT TCG TAT; SEQ ID NO:3) and PNT Xho (GCT CTC GAG ATA ACT TCG TAT AGC ATA CAT TAT ACG AAG TTA TAT GC; SEQ ID NO:4) (150 ng of each) were combined in a 30  $\mu$ l reaction mixture containing 5 U of Klenow polymerase, Klenow polymerase buffer, and 2mM dNTPs (dATP, dCTP, dGTP, and dTTP). After incubating for 1 hour at 37°C, a portion (5 $\mu$ l) of this reaction mixture was simultaneously digested with the restriction enzymes NotI and XhoI to liberate the restriction enzyme sites at each end of the linker. In addition, 200 ng of pPNT was digested with NotI and XhoI. The digested plasmid was resolved on a 0.8% agarose gel, purified from the gel, and treated with calf intestinal phosphatase according to standard methods (Maniatis et al., 1982, *supra*). A quantity (66 ng) of the double digested linker was ligated to the double digested and phosphatase-treated pPNT DNA (Maniatis et al., 1982, *supra*). Following DNA transformation of competent WM1100 *E. coli* (Dower, *Nucleic Acids Res.* 16: 6127-6145, 1988, incorporated herein by reference), plasmid DNA was isolated from ampicillin-resistant bacteria (Holmes et al., *Anal. Biochem.* 114: 193-197, 1981, incorporated herein by reference) and analyzed by restriction enzyme analysis. The proper recombinant plasmids were identified as having acquired SalI, HpaI, and NsiI sites while still retaining the NotI and XhoI sites of the starting plasmid. One such recombinant plasmid with a 79 bp linker sequence was identified and designated pXN-4 (Figure 5).

A similar approach was used to insert a 40 bp 3' linker between the XbaI and BamHI sites of pXN-4. The oligonucleotides used to synthesize the linker were PNT Xba (CGT TCT AGA ATA ACT TCG TAT AAT GTA TGC TAT; SEQ ID NO:5) and PNT Bam (CGT GGA TCC ATA ACT TCG TAT AGC ATA CAT TAT; SEQ ID NO:6). Plasmid pXN-4 and the double-stranded linker DNA were digested with XbaI and BamHI. The purified fragments were joined by DNA ligation and transformed into

- 18 -

competent WM1100 *E. coli* bacteria. Plasmid DNA was digested with *Xba*I and *Bam*HI, end-labelled with  $^{32}$ P-dCTP and Klenow polymerase, and resolved on an 8% acrylamide gel (Maniatis et al., 1982, *supra*). The gel was dried and exposed to X-ray film. Proper recombinant clones were identified by the presence of a 40 bp band liberated by the *Xba*I-*Bam*HI double digest. The resulting plasmid was called pPNTlox<sup>2</sup> (Figure 5). This construct includes the neo<sup>r</sup> flanked by the loxP sequences; see Sauer, *supra*.

To confirm the sequences of the inserted linkers, a fragment containing both linkers was isolated from pPNTlox<sup>2</sup>, using *Not*I and *Eco*RI, and cloned into pBlueScript<sup>®</sup>SK+, a vector more amenable to nucleotide sequencing. Identity of the linkers was confirmed by direct nucleotide sequencing (Sanger, *Proc. Natl. Acad. Sci. USA*, 74: 5463-5467, 1977) using T3 and T7 sequencing primers (Stratagene<sup>®</sup> Inc., La Jolla, CA).

Construction of the pSOD-TV deletion vector: The deletion vector pSOD-TV was assembled by inserting the selected 5' and 3' arms of homology appropriately into pPNTlox<sup>2</sup>. Initially, both arms of homology were subcloned from the phage inserts into pBlueScript<sup>®</sup> SK+. The map of  $\lambda$ SOD18 (Figure 2a) shows restriction enzymes sites for *Kpn*I (K), *Eco*RI (E), *Hind*III (H), and *Sal*I (S). The T3 and T7 promoters at either end of the cloned inserts are indicated. The 3' arm of homology was isolated from  $\lambda$ SOD18 by digesting 10  $\mu$ g of bacteriophage DNA with the enzymes *Kpn*I and *Sal*I, resolving the digested DNA on a 0.8% agarose gel, and purifying the excised 3.3 kb fragment with GeneClean<sup>®</sup> II (Bio 101 Inc., La Jolla, CA). The same digest and gel isolation procedure were performed in parallel with pBlueScript<sup>®</sup>SK+ DNA except that the purified band was 3.0 kb. Approximately 400 ng of the purified lambda DNA and 100 ng of the purified plasmid DNA were combined in a 10  $\mu$ l ligation reaction. Following transformation of competent WM1100 *E. coli*, plasmid DNA was isolated from ampicillin-resistant bacteria and analyzed by restriction enzyme analysis to identify the

- 19 -

resultant plasmid pSK18-9 (Figure 6).

To clone the 3' arm of homology into pPNTlox<sup>2</sup>, the arm was liberated from pSK18-9 by enzymatic restriction with *KpnI* and *EcoRV* and purified by gel isolation. The plasmid pPNTlox<sup>2</sup> was digested with *EcoRI* and the resultant 4 base overhang was filled-in using Klenow polymerase (Maniatis et al., 1982, *supra*). Following further digestion with *KpnI*, the pPNTlox<sup>2</sup> plasmid DNA was gel purified and ligated to the purified 3' arm of homology. Following bacterial transformation, proper recombinants were identified by restriction enzyme analyses. The resulting plasmid was designated pSOD3'homolTV (Figure 7).

A similar approach was used to isolate, purify, and subclone the 5' arm of homology into pBlueScript<sup>®</sup> SK+. The map of  $\lambda$ SOD69 (Figure 2a) shows restriction enzyme sites for *KpnI* (K), *EcoRI* (E), and *HindIII* (H). The T3 and T7 promoters at either end of the cloned insert are indicated. The 5' arm was isolated from  $\lambda$ SOD69 by first digesting the bacteriophage DNA with *HindIII*, isolating an 11.8 kb DNA fragment by gel electrophoresis, and then partially digesting this DNA fragment with limited amounts of *EcoRI* (1U/ $\mu$ g) for 1 to 5 minutes. The reaction was stopped with 20 mM EDTA. A 4.9 kb DNA fragment was purified after agarose gel electrophoresis and cloned into the *EcoRI* and *HindIII* sites of pBlueScript<sup>®</sup> SK+ to generate pSK EH69-2 (Figure 8).

To construct plasmid pSOD-TV, the 5' arm of homology was removed from pSKEH69-2 by first digesting with *NotI*, filling-in the overhang with Klenow polymerase, and then digesting with *SalI*. In parallel, pSOD3'homolTV was first partially digested with *HpaI*, then completely digested with *SalI*. The final deletion vector pSOD-TV was constructed by ligation of the two gel-purified fragments (Figure 9).

- 20 -

**Exempl 3****D 1 t i o n o f t h SOD-1 Gene in ES cells**

Cells: The R1 line of ES cells derived from 129/Sv x 129/Sv-CP F1 hybrid mice (pigmented) (Nagy, et al., *Proc. Natl. Acad. Sci. USA*, 90: 8424-8428, 1993, incorporated herein by reference) was obtained from Dr. Janet Rossant, Dr. Andras Nagy, Reka Nagy, and Dr. Wanda Abramow-Newerly (Mt. Sinai Hospital, Toronto, Ontario, Canada). The cells were grown in ES cell medium consisting of Dulbecco's Modification of Eagle's Medium (Eagle's medium containing L-glutamine and 4500 mg/L glucose; Mediatech Inc., Herndon, VA) supplemented with 20% fetal bovine serum (FBS; Hyclone Laboratories Inc., Logan, Utah; cat. # A-1115; Lot # 11152154), 0.1 mM non-essential amino acids (Mediatech 25-025-L1), 2 mM L-glutamine (Mediatech 25-005-L1),  $10^{-6}$  M  $\beta$ -mercaptoethanol (Gibco 21985-023), 1 mM sodium pyruvate (Mediatech 25-000-L1), 1x concentration of a penicillin (50 IU/ml) streptomycin (50 mcg/ml) solution (Mediatech 30-001-L1), and 1000 U/ml of leukemia inhibitory factor (Gibco BRL 13275-029). The cells were grown on tissue culture plastic that had been briefly treated with a solution of 0.1% gelatin (Sigma G9391), i.e., gelatinized plates.

The cultures were plated at  $1 \times 10^5$  cells per ml in 100 mm X 15 mm plastic culture plates and passaged every 48 hours, or when the cells became about 80% confluent. For passage, the cells were first washed with phosphate buffered saline without  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$ , hereinafter referred to as "PBS", and then treated with a trypsin/EDTA solution (.05% trypsin, .02% EDTA in PBS). After all of the cells were in suspension, the trypsin digestion was stopped by the addition of ES cell medium. The cells were collected by centrifugation, resuspended in 5 ml of ES cell medium, and a 1 ml aliquot of the cell suspension was used to start a new plate of the same size.

DNA Gene-Targeting of ES cells: pSOD-TV DNA (400  $\mu\text{g}$ ) was prepared for electroporation by digesting it with Not I in a 1 ml reaction volume. The DNA was then precipitated by the

- 21 -

addition of ethanol, washed with 70% ethanol, and resuspended in 500  $\mu$ l of sterile water.

The NotI-linearized pSOD-TV DNA was electroporated into ES cells using a Bio-Rad Gene Pulser<sup>®</sup> System (Bio-Rad Laboratories, Hercules, CA) as follows. In each of 10 electroporation cuvettes, 40  $\mu$ g of DNA was electroporated into  $5 \times 10^6$  cells suspended in 0.8 ml ES cell medium. The electroporation conditions were 250 V and 500  $\mu$ F which typically result in time constants ranging between 5.7 - 6.2 seconds. After electroporation the cells were incubated for 20 minutes at room temperature in the electroporation cuvettes. All the electroporated cells were then pooled and distributed approximately equally onto 20 gelatinized plates (100 mm X 15 mm).

After 24 hours, the plates were aspirated and fresh ES cell medium was added. The following day, the medium in 19 plates was replaced with ES cell medium supplemented with 150  $\mu$ g/mL of G418 (Gibco) and 0.2  $\mu$ M ganciclovir (Syntex, Palo Alto, CA). The medium in one plate was supplemented with 150  $\mu$ g/mL of G418 alone. After an additional 6 days, resultant individual ES cell colonies were picked off of the plates and separately expanded in individual wells of 24 well plates as described by Wurst et al., Gene Targeting Vol. 126, Edited by A. L. Joyner, IRL Press, Oxford University Press, Oxford, England, pp. 33-61, 1993, incorporated herein by reference. A comparison of the number of colonies that grew on the plates supplemented with G418 and ganciclovir versus the number that grew on the plates supplemented G418 alone was used to determine the efficiency of negative selection, which was 3.2 fold. Analyses of the gene-targeted ES cells: When the cell culture in each well of the 24-well plates became approximately 80% confluent, the cells were washed with PBS and then dispersed with two drops of trypsin-EDTA. Trypsinization was stopped by the addition of 1 ml of ES cell medium. An aliquot (0.5 mL) of this suspension was transferred to each of two wells of separate 24-well plates.

- 22 -

After the cells had grown to near confluence, one of the plates was used for cryopreservation of the cell line while the other was used as a source of DNA for each of the cloned cell lines.

5           For cryopreservation, the cells in a 24-well plate were first chilled by placing the plate on ice. The medium was then replaced with fresh ES cell medium supplemented with 10% DMSO and 25% FBS. The plate was then cooled at approximately 0.5°C minute by insulating the plate in a  
10 styrofoam box and placing it in a -70°C freezer.

To isolate the DNA from the cloned cell lines on the other 24-well plate, the medium in each well was replaced with 500 µl of digestion buffer (100 mM Tris-HCl, pH8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 100 µg/ml  
15 proteinase K) and incubated overnight at 37°C. After overnight incubation, 500 µl of isopropanol was added to each well and the plate was agitated for 15 minutes on an orbital shaker. The supernatant fluid was aspirated and replaced with 500 µl of 70% ethanol and the plate was shaken  
20 for an additional 15 minutes. The DNA precipitate was picked out of the well and dissolved in 50 µl of TE solution (10 mM Tris-HCl pH 7.5, 1 mM EDTA).

The primary analysis for deletion of the SOD-1 gene involved a Southern hybridization screen of *ApaI* digested ES  
25 cell DNA. The probe for this analysis was derived from the 5' end of the SOD gene outside of the 5' arm of homology (Figure 10a). An aliquot (10 µl) of each DNA sample was digested with *ApaI*, resolved on a 0.8% agarose gel, and transferred to a GeneScreen Plus® membrane. The probe was  
30 prepared by first isolating the 1.3 kb *EcoRI-HindIII* fragment from λSOD69 (Figure 2a). Subsequent *AluI* digest of this fragment yielded the 600 base pair probe. The probe was labelled with <sup>32</sup>P-dCTP by random priming and hybridized overnight to the membrane at 58°C (Church et al., *Proc.*  
35 *Natl. Acad. Sci. USA*, 81: 1991-1995, 1984). An ES cell line in which the SOD-1 gene has been successfully deleted yields 9 kb and 10 kb *ApaI* fragments, in this assay (Figure



- 23 -

- 10). The targeting event replaces all of the SOD-1 coding sequence and introns with the neo<sup>r</sup> positive selection marker. A normal SOD-1 gene carries an ApaI site located approximately 1.0 kb downstream from the 5' border of the region to be deleted. The neo<sup>r</sup> marker which replaces the SOD-1 gene carries with it an ApaI site near its 5' end. As a result, this assay yields a 10 kb ApaI fragment from the normal SOD-1 gene and a 9 kb ApaI fragment from the deleted SOD-1 gene.
- 10 All cell lines scored as putative homologous recombinants by the primary screen were then further screened using a 1.8 kb EcoRI probe (isolated from an  $\lambda$ SOD69, EcoRI digest) on SpeI digested ES cell DNA. In this case, the normal SOD-1 gene yielded a 9 kb fragment and 15 the mutant SOD-1 gene a 10 kb fragment (Figure 10.) From 80 cell lines (numbered 1-80) whose DNA was analyzed, five were identified as having undergone proper homologous recombination. Three of the five cell lines that were identified as having undergone proper homologous 20 recombination by both screens were then thawed and their cell numbers expanded. Cells from the resulting cultures were used to make chimeric mice.

#### Example 4

##### Establishment of SOD-1 Null Mice

- 25 SOD-1 gene-targeted ES cells were used to make chimeric mice by aggregating the ES cells to E2.5 embryos and transferring the aggregated embryos to pseudopregnant females. (Wood et al., Nature, 365: 87-89, 1993, incorporated herein by reference). ES cells were prepared 30 for aggregation by limited trypsinization to produce clumps that averaged 10-15 cells. E2.5 embryos were collected from superovulated CD-1 female mice (albino) by oviduct flushing as described by Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1986). The zona 35 pellucida was removed from the embryos using acidic Tyrode's

- 24 -

solution (Sigma Chemical Co., St. Louis, MO). Aggregation wells were created by pressing a blunt metal instrument i.e., a darning needle into tissue culture plastic.

Embryos were then placed in a well together with a clump of approximately 10-15 ES cells in a small drop (approximately 20  $\mu$ l) of M16 medium (Sigma Chemical Co., St. Louis, MO) under mineral oil. After an overnight incubation (37°C, 100% humidity, 5% CO<sub>2</sub> in air), approximately 20 of the aggregated embryos were transferred to the uterine horns of each pseudopregnant female (Hogan et al., *supra*). Contribution of the ES cells to the offspring was scored by the appearance of pigmented coat color. Pigmented mice were termed chimeric founders. Germline contribution by the ES cells was scored by the appearance of pigmented offspring from a cross between the chimeric founders and CD-1 females.

Three of the five gene-targeted ES cell lines were used in embryo aggregations. One (line 42) gave five germline chimeras, another (line 58) gave four germline chimeras, and the third (line 66) gave none (See Table 1).

20

Table 1

Cell Line Number	Number of Embryo Aggregations	Number of Pups Born	Number of Chimeric Founders	Number of Germline Chimeras
42	138	31	18	5
58	130	24	14	4
25 66	141	33	3	0

The germline chimeras were then used to establish lines of SOD-1 deficient mice and mice lacking SOD-1. The presence of the gene-targeted SOD-1 allele in the pigmented offspring was determined using the Southern blot strategy described above with genomic DNA prepared from a tail sample (Hogan et al., *supra*). Heterozygous SOD-1 null mice have 9 kb and 10 kb *Apa*I fragments that hybridize with the 5' *Alu*I SOD probe. Homozygous SOD-1 null mice were established by

- 25 -

crossing 2 heterozygous SOD-1 null mice and were identified as having only a 9 kb *Apa*I genomic DNA fragment that hybridized with the 5' *Alu*I SOD probe.

#### Example 5

#### 5 Cu/Zn SOD Protein Levels and Enzymatic Activity in the SOD-1 Null Mice

To confirm that the targeted disruption of the SOD-1 locus results in a reduction of Cu/Zn SOD levels in the tissues of the resulting mammals, blood samples were  
10 collected from wild-type mice, and mice shown to be heterozygous and homozygous for the SOD-1 gene. The blood samples were analyzed for Cu/Zn SOD protein by immunoblot analysis. Red blood cell lysates were prepared by lysing the blood cells (approximately 75  $\mu$ l) by several cycles of  
15 alternately freezing and thawing. The protein concentrations of the cell lysates were determined using the BCA method (Pierce, Rockville, IL). An aliquot (2 to 2.5  $\mu$ g of protein) of each sample was electrophoresed on a 4-20% polyacrylamide gel (Novex, San Diego, CA) using a  
20 Tris/glycine/SDS (25 mM Tris/ 192 mM glycine/ 0.1%SDS) buffer system.

The separated proteins were transferred to nitrocellulose filters by electroelution and the resulting filters were blocked by incubation in blotto solution -- 5%  
25 non-fat, dry milk in 25 mM Tris-buffered saline (1x TBS) -- for 30 minutes. The filters were then submersed in a primary antibody solution (1:10,000 dilution in blotto solution) and incubated for between 2 and 18 hours. The primary antibody used was polyclonal rabbit antisera raised  
30 against purified mouse Cu/Zn SOD protein produced in *E. coli* (Hazelton Research Products, Denver, PA). The filters were washed three times for 5 minutes each in 1x TBS and incubated in secondary antibody solution (1:2,000 dilution in blotto solution) for two hours. The secondary antibody  
35 was a goat anti-rabbit IgG conjugated to alkaline phosphatase (Bio-Rad, Richmond, CA). The filters were

- 26 -

washed three times for 5 minutes each in 1x TBS and stained for alkaline phosphatase activity by incubating them for between 5 and 60 minutes in a commercially available alkaline phosphatase detection reagent (Bio-Rad, Richmond, CA).

Stained bands corresponding to Cu/Zn SOD protein were quantitated using a DocuGel V image analysis system and RFLPscan software (Scanalytics, Billerica, MA). The levels of Cu/Zn SOD protein are depicted in Figure 11 (solid bars) and are expressed relative to the level of Cu/Zn SOD protein in the samples from wild-type mammals. The results of these studies indicate that the heterozygous SOD-1 null mice exhibit an expected near 50% reduction in Cu/Zn SOD protein. Further, the homozygous SOD-1 null mammals showed no detectable Cu/Zn SOD protein on Western blots.

Cu/Zn SOD enzymatic activity in the red blood cell lysates was measured using the NADPH oxidation method of Paoletti, et al. (*Anal. Biochem.*, 154:536-541, 1986, incorporated herein by reference). Protein samples (1 mg) from the wild-type, heterozygous SOD-1 null mice, and homozygous SOD-1 null mice were extracted with an equal volume of ethanol:chloroform (2:1) and the resulting supernatant fluid was dialyzed overnight against PBS saline at 4°C. The protein concentration of the dialysate was determined using the BCA method (Pierce, Rockville, IL) and 10 ug of each sample was assayed for SOD activity. Enzymatic activity was expressed relative to the wild-type control sample (Figure 11, cross-hatched bars). The Cu/Zn SOD activity of the sample from heterozygous SOD-1 null mammals was approximately 50% of that displayed by samples from the wild-type mammals, consistent with the expectation that only one SOD-1 allele was active in the heterozygous mammals. Furthermore, the protein sample derived from the homozygous SOD-1 null mice showed nearly a total reduction in Cu/Zn SOD activity. The small residual activity detected in this assay likely represents background activity associated with the assay, but could also reflect an

- 27 -

endogenous superoxide scavenging activity supplied by an alternate protein.

#### **Example 6**

##### **Maintenance conditions of SOD-1 Null Mice**

5        Young adult heterozygous and homozygous SOD-1 null mice are currently being maintained under viral and antigen free conditions as defined by Charles River Laboratories, Wilmington, MA. Presently, the diet for these mice is the same as that provided to laboratory mice. No other unique  
10 or distinguishing living conditions have thus far been required for the mice.

      Attempts at the breeding of homozygote males with homozygote females have been unsuccessful thus far, which we believe is due to the deficiency of Cu/Zn SOD and the  
15 oxidative stress occasioned by pregnancy. The homozygote breeding pairs are capable of conceiving offspring, but the litters have been small in number (1-2) and the pups are either still-born, or those pups which are born alive die almost immediately.

20        The colony can be propagated by the breeding of heterozygous SOD-1 null males and females, homozygous SOD-1 null males to either wild type or heterozygous SOD-1 null females, or wild type males to homozygous SOD-1 null females.

25        While the invention has been described and illustrated with respect to specific embodiments, it is to be understood that modifications and equivalents apparent to those skilled in the art are intended to be within the scope of the disclosure and the following claims.

30        All references referred to herein are hereby incorporated by reference.

- 28 -

What is claim d is:

1. A heterozygous SOD-1 null mouse.
2. A homozygous SOD-1 null mouse.
3. A gene-targeted mouse lacking at least one normal SOD-1  
5 allele.
4. The mouse of claim 3 substantially lacking both normal SOD-1 alleles.
5. A gene-targeted mouse having a phenotype characterized by a reduced amount of Cu/Zn SOD protein expression.
- 10 6. The gene-targeted mouse of claim 5 wherein substantially no measurable amount of Cu/Zn SOD is produced by said mouse.
7. A recombinant DNA construct comprising a first sequence homologous to a sequence from the 5' flanking region of  
15 genomic SOD-1 from a mammal, a second sequence homologous to a sequence from the 3' flanking region of genomic SOD-1 from said mammal, and a positive selection marker.
8. The DNA construct of claim 7 further comprising a negative selection marker.
- 20 9. The DNA construct of claim 8 wherein said first sequence is about 4.9 kb and said second sequence is about 3.3 kb.
10. The DNA construct of claim 7 further wherein said first and second sequences are substantially isogenic to genomic  
25 SOD-1 of a select cell from said mammal.

- 29 -

11. The DNA construct of claim 10 wherein said cell is an embryonic stem cell.

12. A method for assessing the effectiveness of a compound for counteracting the deleterious effects of oxidative stress comprising:  
5 a) exposing a heterozygous or homozygous SOD-1 null gene-targeted mouse to oxidative stress;  
b) administering said compound to said mouse; and  
c) comparing results obtained with said compound to a  
10 control.


13. A method for assessing the effectiveness of a compound for counteracting the deleterious effects of oxidative stress comprising:  
a) exposing cells from a heterozygous or homozygous  
15 SOD-1 null gene-targeted mouse to oxidative stress;  
b) administering said compound to said cells; and  
c) comparing results obtained with said compound to a control.

14. A gene-targeted non-human mammalian cell lacking at  
20 least one normal SOD-1 allele.

15. The cell of claim 14 wherein said cell is an embryonic stem cell.

16. The cell of claim 15 wherein said embryonic stem cell is obtained from a mouse.

1/11


Figure 1**Prototype Gene Targeting Strategy**



2/11

Figure 2

## Mouse SOD-1 Genomic Clone Maps



3/11

## Restriction Mapping With FLASH™ Gene Mapping Kit

Figure 3





Figure 4


SOD Genomic Map & pSOD-TV Deletion Vector



5/11

pPNTlox<sup>2</sup> Synthesis


Figure 5




6/11

## pKS18-9 Construction

Figure 6




7/11

**pSOD3'HomolTV Construction****Figure 7**

8/11

Figure 8


## pSK EH69-2 Construction



9/11

## pSOD-TV Construction

Figure 9






10/11


**Figure 10**

Strategy to detect homologous recombination within mouse SOD-1



11/11

FIGURE 11



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/02751

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 49/00; C07H21/04; C12N 5/06, 15/06, 15/07

US CL : 424/9.1, 9.2; 435/172.3, 240.2, 240.21, 320.1; 536/24.1; 800/2

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/9.1, 9.2; 435/172.3, 240.2, 240.21, 320.1; 536/24.1; 800/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BRADLEY, A. et al. Modifying the mouse: Design and Desire. Biotechnology. May 1992, Volume 10, pages 534-539, see entire article.	1-16
Y	BOWLING, A.C. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. Journal of Neurochemistry. 1993, Volume 61, No. 6, pages 2322-2325, see entire article.	1-16

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 JUNE 1996

Date of mailing of the international search report

12 JUL 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRIAN R. STANTON

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/02751

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PHILLIPS, J.P. et al. Null mutation of copper/zinc superoxide dismutase in Drosophila confers hypersensitivity to paraquat and reduced longevity. Proceedings of the National Academy of Science, USA. 1989, volume 86, pages 2761-2765, see entire article.	1-16
Y	BENEDETTO, M.T. et al. Isolation and analysis of the mouse genomic sequence encoding Cu <sup>2+</sup> -Zn <sup>2+</sup> superoxide dismutase. Gene. 1991, Volume 99, pages 191-195, see entire article.	1-16
Y	CAPECCHI, M.R. The new mouse genetics: Altering the genome by gene targeting. Trends in Genetics, 1989, Volume 5, No. 3, pages 70-76, see entire article.	1-16
Y	DENG H-X et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science, 20 August 1993, pages 1047-1051, see entire article.	1-16

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/02751

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

Databases: Aidsline; anabstr; aquasci; biusiness; niosis; biotechds; caba; cancerlit; caplus; ca; ceaba; cen; cin; cjac; cjelsevier; confsci; cropb; dgene; dissabs; druglaunch; drugnl; drugu; embal; embase; fsta; genbank; healsafe; ifipat; jicst-eplus; jpnews; lifesci; medline; ntis; ocian; phic; phin; prompt; scisearch; topline; toxlit; uspatfull; APS

Search Terms: sod?; superoxide; dismutase?; transgen?; homologous; recombination; embryonic; stem; oxidat?; scott?/au; reaume?/au; hoffman?/au

